CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors

INTRODUCTION: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on health...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragon, Anna Christina, Beermann, Luca Marie, Umland, Melina, Bonifacius, Agnes, Malinconico, Chiara, Ruhl, Louisa, Kehler, Patrik, Gellert, Johanna, Weiß, Lisa, Mayer-Hain, Sarah, Zimmermann, Katharina, Riese, Sebastian, Thol, Felicitas, Beutel, Gernot, Maecker-Kolhoff, Britta, Yamamoto, Fumiichiro, Blasczyk, Rainer, Schambach, Axel, Hust, Michael, Hudecek, Michael, Eiz-Vesper, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616308/
https://www.ncbi.nlm.nih.gov/pubmed/37915564
http://dx.doi.org/10.3389/fimmu.2023.1219165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616308/
https://www.ncbi.nlm.nih.gov/pubmed/37915564
http://dx.doi.org/10.3389/fimmu.2023.1219165

Ejemplares similares